Genetic Technologies LimitedNASDAQ: GENE

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's

GeneDx Holdings WGS stock is trading higher on Tuesday.

Myriad's MyRisk®  test is the first hereditary cancer test integrated into Flatiron's OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Flatiron Health, a leading health tech company dedicated to expanding the possibilities of point of care solutions in oncology. This collaboration allows physicians to order Myriad's MyRisk®  Hereditary Cancer Test and view the results of the test directly in Flatiron's cloud-based Electronic Medical Record (EMR) platform, OncoEMR®.

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November

Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data from the Company's Rostock International Parkinson's Disease (ROPAD), further supporting the association of a RAB32 gene mutation with Parkinson's disease (PD). The study, published in The Lancet Neurology , builds on research from Emil K. Gustavsson and colleagues, who previously identified the RAB32 c.213C>G (p.Ser71Arg; dbSNP rs200251693) variant as a novel monogenic cause of PD.

Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics

WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan's 8th Annual Genetic Medicines Conference being held in New York on Monday, September 30, 2024 at 2:00 p.m. ET.

MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET.